Targets › PKD1
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Nov 2028.
Component of a heteromeric calcium-permeable ion channel formed by PKD1 and PKD2 that is activated by interaction between PKD1 and a Wnt family member, such as WNT3A and WNT9B. Both PKD1 and PKD2 are required for channel activity. Involved in renal tubulogenesis. (UniProt, P98161)
Open in Phaseline: the race on PKD1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| PYC Therapeutics | PYC-003 Peptide-phosphorodiamidate morpholino oligonucleotide conjugate targeting PKD1 | PKD1 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Nov 2028 |
Autosomal Dominant Polycystic Kidney Disease (ADPKD) (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.